



Main: (305) 892-1035
Fax: (305) 892-1038
24hrs: (305) 892-1037
Located in: Jackson South Medical Plaza
15155 SW 97 AVE Suite 220, Miami, FL 33176
www.newgenhealth.org

SOUTH FLORIDA INDEPENDENT CLINICAL RESEARCH INSTITUTION

10+ Years

Clinical Research Experience

30,000+

Accessible Patient Database

Phase II-IV

Operational Trial Capability

Jackson South

Hospital Adjacent Location

Bilingual

English/Spanish Recruitment

Full Service

Lab + Imaging + Device Support

INSTITUTIONAL OVERVIEW

NewGen Health Group is a high-performing independent clinical research site strategically located within Jackson South Medical Plaza in Miami, Florida, directly adjacent to Jackson South Community Hospital. The institution is supported by an integrated network of board-certified specialists, certified coordinators, licensed nurses, laboratory technicians, and regulatory personnel, providing sponsors with a streamlined and responsive environment for clinical trial execution. NewGen has built a reputation for rapid activation, exceptional patient retention, and strong sponsor communication.

FACILITY INFRASTRUCTURE & DIAGNOSTIC ACCESS



NewGen Health Group has dedicated informed consent areas, 5 exam rooms, EKG rooms, conference room, administrative suite, fully functional laboratory, double-locked investigational product storage and patient records room. On-site equipment includes 20°C and -80°C freezers, ambient and refrigerated centrifuges, oxygen support, spirometer, EKG, Doppler, blood pressure monitors, Ophthalmoscope / Otoscope / Laryngoscope, defibrillator, and bariatric scale. Through its medical plaza and hospital affiliations, NewGen maintains direct access to MRI, CT, DEXA, Ultrasound, X-Ray, Biopsy, and additional ancillary testing services.

THERAPEUTIC DEPTH & INVESTIGATOR NETWORK

NewGen Health Group routinely conducts research in Cardiology, Pulmonology, Psychiatry, Neurology, Infectious Disease, Gastroenterology, Internal Medicine, Endocrinology, Women's Health, Hematology, Rheumatology, Dermatology, Vaccines, Musculoskeletal, and Geriatric Medicine. The site is supported by 11 board-certified specialists across multiple therapeutic areas, providing extensive clinical expertise and a strong referral network. This multidisciplinary infrastructure enables immediate specialty feasibility review, efficient patient identification, and accelerated access to protocol-specific populations.

PATIENT RECRUITMENT MODEL

NewGen leverages multiple enrollment channels including hospital referrals, private physician referrals, EMR/database pre-screening, community physician partnerships, bilingual community outreach, digital/social media advertising, transportation support, and family/caregiver engagement. This layered model consistently provides access to diverse Hispanic, African American, Caucasian, and elderly patient populations across South Florida, allowing efficient recruitment for both chronic disease and acute indication studies.



HEALTH & RESEARCH GROUP

☎ **Main:** (305) 892-1035
☎ **Fax:** (305) 892-1038
☎ **24hrs:** (305) 892-1037
📍 **Located in:** Jackson South Medical Plaza
15155 SW 97 AVE Suite 220, Miami, FL 33176
🌐 **www.newgenhealth.org**

CURRENT ACTIVE STUDIES / RECENT SPONSOR EXPERIENCE

Sponsor	Study Program
AstraZeneca	Phase III Balcinrenone/Dapagliflozin Heart Failure & Impaired Kidney Function Outcomes Trial
Fisher & Paykel Healthcare	myAirvo 3 High Flow Nasal Therapy Multi-Center COPD Home Management Trial
Philip Morris Products S.A.	Controlled COPD Chronic Bronchitis Symptom and Function Switching Study
Locus Biosciences	ELIMINATE Trial – Phase II Drug Resistant E. coli Acute Uncomplicated UTI Program
Karuna Therapeutics	ADEPT-4 Phase III KarXT for Psychosis Associated with Alzheimer’s Disease
Karuna Therapeutics	ADEPT-3 Open Label Long-Term Safety Extension for Alzheimer’s Disease Psychosis

UPCOMING STUDIES

Sponsor	Study Program
AstraZeneca	Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)
Castle Bioscience	Development and Validation of a Cytology Based Assay, Using a Swallowable Cell Collection Device (CCD) in Patients at Risk for Barrett’s Esophagus and Esophageal Neoplasia (Valor)

SPONSOR VALUE PROPOSITION

- Independent site leadership with direct decision-making and minimal bureaucratic delays
- Rapid budget, contract, and regulatory turnaround
- Experienced execution of device, pharmaceutical, and interventional protocols
- High-value access to Cardiology, Pulmonology, Psychiatry, Infectious Disease, and Internal Medicine populations
- Dedicated sponsor communication with real-time enrollment reporting and proactive issue resolution
- Strong retention model supported by transportation assistance and bilingual patient navigation

SPONSOR / CRO BUSINESS DEVELOPMENT CONTACT

Morayma Ramos | Director of Research Business Development
m.ramos@newgenhealth.org | (305) 892-1035 | 24-Hour: (305) 892-1037
15155 SW 97 Avenue, Suite 220, Miami, FL 33176
www.newgenhealth.org